Australian Cancer Plan recognises crucial role of pharmaceutical, biotherapeutics and vaccine industry.

3 November 2023: Medicines Australia welcomes Australia’s landmark national Cancer Plan, which recognises the crucial role of the pharmaceutical, biotherapeutics and vaccine industry in the prevention, detection, management and treatment of cancers.

Medicines Australia CEO Liz de Somer said the six strategic objectives in the Plan reflect the priorities called for by stakeholders including industry and she welcomed the focus on prevention, early detection and treatment and increased workforce capability.

“Medicines Australia congratulates the Minister for Health and Aged Care, Department of Health and Cancer Australia on producing this landmark Plan that recognises holistic change and collaboration is needed to end the devastating impact of cancer on our society.”

“Over the last 40 years, the pharmaceutical industry has invested significantly in the research and development of innovative new vaccines, diagnostics and therapies,” Ms de Somer said.

“This perseverance has led to a new era where genomic testing and personalised medicine are now available and improving the prognosis and quality of life of many patients.

“The Plan recognises this but it also recognises that access to early diagnostic technology and treatment options through the PBS remains the biggest hurdle for too many Australians.

“This must be addressed through HTA reforms if Australia is to have a world class health system.”

Medicines Australia welcomes the commitment to a new policy framework for genomics in cancer control and the establishment of an Australian Comprehensive Cancer Network (ACCN) to share expertise and reduce access inequity.

“We agree with the identified need in the Plan for system-wide, cross-sector, inter-jurisdictional and national collaboration,” Ms de Somer said.

“The pharmaceutical industry will continue to work closely with patients, governments, universities and other stakeholders to advance our health system for the benefit of patients, and ensure everyone has access to the right vaccines, diagnostics and treatments when they are needed.”

Media enquiries to Kate McKeown, Senior Manager Communications and Media – or 0408 775 288.